

## **Supporting Information**

### **Molecular Dynamics Simulations for Human CAR Inverse Agonists**

*Johanna Jyrkkärinne\*, Jenni Küblbeck, Juha Pulkkinen, Paavo Honkakoski, Reino*

*Laatikainen, Antti Poso and Tuomo Laitinen\**

University of Eastern Finland, Faculty of Health Sciences, School of Pharmacy, PO Box 1627,  
FI-70211 Kuopio, Finland

\*To whom the correspondence should be addressed:

Tel. +358 40 3552520 or +358 400 165489

Johanna.Jyrkkarinne@uef.fi, Tuomo.Laitinen@uef.fi

**Table S1.** Cytotoxicity data from MTT tests for the studied ligands.

<b>Ligand<sup>a</sup></b>	<b>Fold absorbance<sup>b</sup> (DMSO = 1)</b>
<b>CITCO</b>	1.09 ± 0.07
<b>FL-82</b>	0.97 ± 0.02
<b>FL-81</b>	0.92 ± 0.01
<b>Permethrin</b>	0.80 ± 0.11
<b>Clotrimazole</b>	1.02 ± 0.02
<b>TPP</b>	1.21 ± 0.04
<b>Artemisin</b>	1.08 ± 0.10
<b>EE2*</b>	0.93 ± 0.16
<b>Androstanol</b>	n.d. <sup>c</sup>
<b>Androstenol*</b>	0.75 ± 0.08
<b>PK11195</b>	1.03 ± 0.03
<b>S07662</b>	1.13 ± 0.09
<b>Clomifene</b>	n.d. <sup>c</sup>
<b>Celecoxib</b>	0.98 ± 0.02
<b>Meclizine</b>	1.26 ± 0.09
<b>HgCl<sub>2</sub><sup>d</sup></b>	0.04 ± <0.01

<sup>a</sup>The concentration of ligand was 10 µM. For the ligands marked with “\*” 50 µM concentration was used.


<sup>b</sup>Fold absorbance (vehicle control DMSO = 1) measured at 570 nm ± s.d.

<sup>c</sup>No data for MTT tests is available. No toxicity of these compounds was observed at 30 µM concentration when looking at the expression of β-galactosidase reporter gene which was used as a transfection control in M1H and M2H assays.


<sup>d</sup>Positive control (0.1 mM) for toxicity.

	<b>H3-H4</b>	<b>H12</b>
<u>hCAR</u>	LQVIKFTKDLFVFRSLPIEDQISLLKGA	PLLQEICS---
<u>hPPAR<math>\gamma</math></u>	TELTEFAKAIPGFANLDLNDQVTLLKYG	PLLQEIYRDMY
	: : : * : * * . * : : * * : : * * * .	*****
	<b>CoR Interaction domains</b>	
<u>SMRT</u>	NMGLEAIIRKALMGKYDQW	
<u>NCoR</u>	NLGLEDIIRKALMGSFDDK	
	* : * * * * * * * * * * . : * :	

**Figure S1.** The alignment of co-regulator interacting regions (c-terminal part of H3, H4 and H12) of hCAR and PPAR $\gamma$  and the alignment of interaction domains of SMRT and NCoR. Identical residues have been identified with “\*”, conserved substitutions with “:” and semi-conserved substitutions with “.” The most important and conserved residues in the NR interaction of SMRT and NCoR have been high-lighted with grey.



**Figure S2.** APFs of CAR LBD backbone during MDs with A) agonists and B) inverse agonists.



**Figure S3.** Position of H12 in the final structures of the MDs. Apo structure is shown in blue as a reference with each liganded structure (green).